A clinical example of the latter is described in an interesting review discussing the importance of angiogenesis and the pro-angiogenic and pro-myogenic effects of the vascular endothelial growth factor (VEGF)/VEGF receptor pathway as a therapeutic strategy to cure muscle weakness and cardiomyopathy in Duchenne muscular dystrophy (DMD) patients (Shimizu-Motohashi and Asakura, 2014). This evidence concerns the gene VEGFA and Duchenne muscular dystrophy.